David Geffen School of Medicine, UCLA, Los Angeles, CA 90036, USA.
Headache. 2012 Apr;52(4):701-6. doi: 10.1111/j.1526-4610.2012.02123.x.
Old headache medicines never die; they either fade away or come back in disguise. The disguise is often a new route of administration, which may work better, faster, more completely, with fewer adverse events, and/or have certain other advantages. The clinical aspects of 3 of the oldest headache medicines (ergotamine tartrate, dihydroergotamine, and methysergide) will be discussed here. Sumatriptan will then be discussed as the prototype of the newest category of acute care therapy (triptans) for migraine. It will be compared with the older medications, and the new forms being developed will be briefly discussed. Diclofenac potassium for oral solution will be mentioned as the newest drug approved for migraine by the Food and Drug Administration, and a possible alternative to triptans in patients with frequent headaches or those with contraindications to vasoconstrictors.
老的头痛药物不死;它们不是消失就是改头换面地回来。这种伪装通常是一种新的给药途径,它可能会更好、更快、更完全地发挥作用,不良反应更少,或者具有某些其他优势。本文将讨论 3 种最古老的头痛药物(酒石酸麦角胺、二氢麦角胺和麦角乙脲)的临床方面。然后,舒马曲坦将作为偏头痛最新类别急性治疗药物(曲坦类药物)的原型进行讨论。它将与旧药物进行比较,并简要讨论正在开发的新形式。双氯芬酸钾口服溶液将被提及为食品和药物管理局批准用于偏头痛的最新药物,并可能成为有频繁头痛或对血管收缩剂有禁忌症的患者的曲坦类药物的替代药物。